Still Independent, Shire Continues With Goals Modeled On Celgene, Gilead, Biogen Idec
This article was originally published in The Pink Sheet Daily
Executive Summary
While the proposed merger with AbbVie, abandoned on Oct. 20, took a lot of energy, it did not deter Shire from pursuing its stated strategy, CEO Ornskov tells “The Pink Sheet” DAILY. The specialty firm reported a strong third quarter, with rare disease product sales up 66%.